CDNA Stock Risk & Deep Value Analysis
CareDx Inc
Healthcare • Diagnostics & Research
DVR Score
out of 10
The Bottom Line on CDNA
We analyzed CareDx Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran CDNA through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Here's what we found.
Get notified when CDNA moves
Same alert types as Telegram — presets or custom thresholds in your 🔔 feed.
📈CDNA Performance Overview3yr weekly
Unlock CDNA Performance Chart
See 3 years of price history, quarterly revenue trends, and DVR score changes
Weekly adjusted close · Quarterly revenue & EPS · DVR score history
CDNA Quality Rating
CDNA Stock Risk Analysis
Overall Risk
Aggressive
Financial Risk
High
Market Risk
Medium
About CareDx Inc (CDNA)
Sector
Healthcare
Industry
Diagnostics & Research
Market Cap Category
small
Market Cap
$937.77M
CDNA Deep Value Analysis
CDNA Research Sources
No external source links for this analysis yet. Run a fresh analysis to capture SEC filings and financial news articles we used.
For educational context only. Not financial advice.
CDNA Red Flags & Warning Signs
- ⚠
Continued EPS misses or declining revenue growth in upcoming quarters
- ⚠
Increased competitive pressure from rivals in transplant diagnostics
- ⚠
Adverse outcomes in existing or new legal challenges
Unlock CDNA Red Flags & Risk Warnings
Premium members see every risk event we found.
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
Unlock everything for $47/yr
$79/yrSave 41%
- ✓ Catalysts, bull case, moat & red flags
- ✓ Unlimited stock analyses + alerts
- ✓ Full database, search & portfolio (50 stocks)
7-day money back · Cancel anytime
CDNA Financial Health Metrics
Market Cap
$937.77M
P/E Ratio
15.00
Profit Margin
17.06%
Debt-to-Equity
0.09
Dividend Yield
0.00%
Beta (Volatility)
1.15
Earnings Per Share
$1.00
CDNA Competitive Moat Analysis
Moat Rating
Narrow
Moat Trend
Eroding
Moat Sources
2 Identified
The moat is vulnerable to erosion from new, more accurate, or cost-effective diagnostic technologies emerging from competitors, as well as the expiration of key patents. The intense competitive landscape puts continuous pressure on pricing and innovation.
CDNA Competitive Moat Analysis
Premium unlocks moat rating, sources & durability.
CDNA Catalysts & Growth Drivers
Near-Term (0-6 months)
- •Q1 2026 Earnings Report on 2026-04-29
Medium-Term (6-18 months)
- •Potential stabilization of revenue trends and return to positive operating cash flow (if achieved)
- •Resolution of competitive pressures or legal disputes (no specific timeline)
Long-Term (18+ months)
- •Successful product innovation or market expansion within transplant diagnostics (no specific plan identified)
- •Demonstrated ability to achieve and sustain profitability
Catalysts & Growth Drivers
Sign up free to see growth catalysts
CDNA Bull Case: What Could Go Right
- ✓
Consistent quarter-over-quarter revenue growth acceleration.
- ✓
Clear pathway and execution towards sustained positive free cash flow.
- ✓
Announcements of new strategic partnerships or significant product pipeline advancements.
- ✓
Positive resolution of legal disputes or competitive landscape stabilization.
Bull Case Analysis
Sign up free to see the bull case
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential.
FAQ
What is the DVR Score for CareDx Inc (CDNA)?
As of April 6, 2026, CareDx Inc has a DVR Score of 1.9 out of 10, placing it in the "Distressed" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of CareDx Inc?
CareDx Inc's market capitalization is approximately $937.8M. The company operates in the Healthcare sector within the Diagnostics & Research industry.
What ticker symbol does CareDx Inc use?
CDNA is the ticker symbol for CareDx Inc. The company trades on the NGM.
What is the risk level for CDNA stock?
Our analysis rates CareDx Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of CDNA?
CareDx Inc currently has a price-to-earnings (P/E) ratio of 15.0. This is below the market average, which could indicate the stock is undervalued or facing headwinds.
Is CareDx Inc's revenue growing?
CareDx Inc has reported revenue growth of 0.0%. Revenue has been declining, which warrants closer examination.
Is CDNA stock profitable?
CareDx Inc has a profit margin of 17.1%. The company is profitable but margins are modest.
How often is the CDNA DVR analysis updated?
Our AI-powered analysis of CareDx Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on April 6, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research and consult with a qualified financial advisor.